Abstract:Autologous hematopoietic stem cell transplantation (ASCT) improves survival for patients with chemotherapy-sensitive lymphoma. Validated scoring systems are used in the clinical setting to predict treatment toxicity and survival; however, complications related to disease and treatment still occur, highlighting challenges in optimal patient selection and the need for novel predictors. Analysis of body composition and muscle mass can provide an objective assessment to identify vulnerable populations, as sarcopenia and frailty have been reported to predict outcomes in other tumor types. In this retrospective cohort study of patients undergoing ASCT for lymphoma, we investigated associations of sarcopenia with clinically significant outcomes, including overall survival (OS) and progression-free survival (PFS). Computed tomography (CT) images of 78 patients obtained routinely pretransplantation were used to assess skeletal muscle mass and are reported as skeletal muscle index (SMI). OS, PFS, and clinical outcomes of interest were compared between groups. Twenty-seven patients (34.6%) in the cohort met the criteria for sarcopenia. Patients with sarcopenia had a significantly shorter 3-year PFS (59% [95% confidence interval (CI), 38% to 75%] versus 84% [95% CI, 71% to 92%]; P = .02) after 3 years of follow up, whereas there was no difference in OS between patients with and those without sarcopenia (78% [95% CI, 57% to 89%] versus 88% [95% CI, 76% to 95%]; P = .25). Interestingly, no difference in survival was found with stratification based on the Karnofsky Performance Scale or Hematopoietic Cell Transplantation-Specific Comorbidity Index. There also were no significant between-group differences in length of hospital stay and the incidences of other clinical outcomes of interest, including febrile neutropenia, mucositis, total parenteral nutrition requirement, acute kidney injury, rate of readmission, or intensive care unit admission. This is the first study to our knowledge to correlate sarcopenia with disease control and PFS after ASCT in lymphoma. Possible explanations include a higher rate of chemotherapy-related toxicity, leading to disruptions of treatment as well as dysfunction of antitumor immunity secondary to impaired regulations from myokines from the loss of muscle mass or an unknown cause that is yet to be elucidated. Physical therapy programs and personalized regimens for treatment based on the analysis of body composition indices can be further studied and implemented to mitigate treatment-related toxicity and to optimize survival in patients with sarcopenia.

Sarcopenic obesity in survivors of childhood acute lymphoblastic leukemia: prevalence, risk factors, and implications for cancer survivors

Sarcopenic obesity in cancer

Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy

Sarcopenia Prevalence in Patients with Cancer and Association with Adverse Prognosis: A Nationwide Survey on Common Cancers.

Obesity and Metabolic Disease After Childhood Cancer

Sarcopenic Obesity and Outcomes for Patients With Cancer

Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Adiponectin correlates with obesity: A study of 159 childhood acute leukemia survivors from India

Prevalence of sarcopenic obesity in patients with gastric cancer and effects on adverse outcomes: a meta-analysis and systematic review

Serum Adipokines as Biomarkers for Surveillance of Metabolic Syndrome in Childhood Acute Lymphoblastic Leukemia Survivors in Low Middle-Income Countries

Prognostic Value of Sarcopenia in Survivors of Hematological Malignances Undergoing a Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-Analysis

The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature

Sarcopenia in cancer survivors is associated with increased cardiovascular disease risk

Prevalence and Prognostic Value of Sarcopenic Obesity in Patients with Cancer: A Systematic Review and Meta-Analysis

Sarcopenia Predicts Inferior Progression-Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation

Clinical Impact of Sarcopenia for Overweight or Obese Patients with Colorectal Cancer

Sarcopenia and malignancies: epidemiology, clinical classification and implications

Sarcopenic Obesity in Cervical Carcinoma: A Strong and Independent Prognostic Factor beyond the Conventional Predictors (ESTHER Study—AFRAID Project)

Association of Possible Sarcopenia with All-Cause Mortality in Patients with Solid Cancer: A Nationwide Multicenter Cohort Study.

Sarcopenia is Prevalent in Cancer Patients and is Associated with Adverse Prognosis: A Nationwide Survey on Common Cancers

Prevalence of Sarcopenia in Women with Breast Cancer